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introduction
Bioluminescence imaging (BLI) using luciferase reporters 
has been indispensible for noninvasive monitoring of differ-
ent biological processes such as tumor volume and transcrip-
tional activation during tumor development/therapy, as well as 
immune cell infiltration into the tumor environment.1 Unlike end-
point analysis, BLI provides real-time, noninvasive assessment 
of in situ biological events, thereby giving a better “picture” of 
the kinetics of an entire process. Great strides have been made 
since the first demonstration of in vivo BLI.2 For example, as few 
as 10 cells expressing firefly luciferase (Fluc) can be detected 
in deep tissue in some animal models.3 Additional progress 
has been made by the discovery and molecular construction 
of different luciferases with a multitude of properties, including 
secreted reporters such as Gaussia luciferase (Gluc),4 multi-
color light emission spectra for better tissue penetrance in vivo 
and spectral deconvolution,5,6 increased thermostability,7 and 
light output.8,9 One limitation to current bioluminescence imag-
ing is that typically only one and at most two luciferase report-
ers are used to measure one or two parameters.10–12 As tumor 
formation is a complex process, concurrent measurement of 
several events will be important for the development of novel 
therapeutics and their transition to the clinic.
In this study, we have characterized a codon-optimized 
Vargula hilgendorfii luciferase (Vluc) for mammalian gene 
expression, and showed that this luciferase can be multi-
plexed with Gluc and Fluc for sequential imaging of three dif-
ferent biological processes in the same biological system. We 
then applied this triple imaging system to monitor the effect 
of adeno-associated virus (AAV)-mediated soluble tumor 
necrosis factor-related apoptosis-inducing ligand (sTRAIL) 
therapy against intracranial glioma tumors.
Results
Characterization of a codon-optimized Vluc for 
 mammalian gene expression
We first cloned Vluc cDNA, codon-optimized for mammalian 
gene expression, into a lentivirus vector under the control of 
the cytomegalovirus promoter (Lenti-Vluc). This vector also 
expresses the mCherry fluorescent protein separated from 
Vluc by an internal ribosomal entry site, used to monitor trans-
duction efficiency. Since Vluc cDNA carries a natural signal 
sequence,13 it is secreted to the conditioned medium once 
expressed in mammalian cells. We first observed the level 
of Vluc secretion by transducing 293T cells with Lenti-Vluc 
and evaluating the Vluc levels in cell lysates and conditioned 
medium using the vargulin substrate. We observed that the 
majority of Vluc activity (78%) was contained in the medium 
fraction showing efficient secretion (Figure 1a). Next, we evalu-
ated the light emission kinetics of Vluc over time and observed 
a slow decay in light emission, with 44% of the initial signal 
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Bioluminescence imaging (BLI) has shown to be crucial for monitoring in vivo biological processes. So far, only dual 
 bioluminescence imaging using firefly (Fluc) and Renilla or Gaussia (Gluc) luciferase has been achieved due to the lack of 
 availability of other efficiently expressed luciferases using different substrates. Here, we characterized a codon-optimized 
 luciferase from Vargula hilgendorfii (Vluc) as a reporter for mammalian gene expression. We showed that Vluc can be  multiplexed 
with Gluc and Fluc for sequential imaging of three distinct cellular phenomena in the same biological system using vargulin, 
coelenterazine, and d-luciferin substrates, respectively. We applied this triple imaging system to monitor the effect of soluble 
tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL) delivered using an adeno-associated viral vector (AAV) on 
brain tumors in mice. Vluc imaging showed efficient sTRAIL gene delivery to the brain, while Fluc imaging revealed a robust 
antiglioma therapy. Further, nuclear factor-κB (NF-κB) activation in response to sTRAIL binding to glioma cells death receptors 
was monitored by Gluc imaging. This work is the first demonstration of trimodal in vivo bioluminescence imaging and will have 
a broad applicability in many different fields including immunology, oncology, virology, and neuroscience.
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remaining 5 minutes after substrate addition (Figure 1b). To 
further characterize Vluc as a mammalian cell reporter, we 
measured the stability of the enzyme over time at 37 °C. Con-
ditioned medium from cells expressing Vluc were incubated at 
37 °C in a humidified cell incubator. Aliquots were taken at dif-
ferent time points and assayed for Vluc activity. We observed 
that Vluc levels retained full activity over 12 days indicating 
high enzyme stability in conditioned medium (Figure 1c), sim-
ilar to that reported for the secreted Gaussia luciferase.14 We 
next evaluated Vluc as a reporter to monitor cell viability and 
proliferation over time. U87 glioma cells transduced with Lenti-
Vluc were seeded in a culture well and aliquots of conditioned 
media were collected at different time points and analyzed for 
Vluc activity. In parallel, a commercially available Fluc-based 
viability assay was performed for comparison. We observed 
a high correlation (r2 = 0.98) between the Vluc assay and the 
established viability assay (Figure 1d).
Optimization of the triple in vivo bioluminescence 
 imaging system
To validate Vluc as a reporter for in vivo imaging, we first 
characterized its bioluminescence reaction properties in 
a quantitative tumor model. Nude mice were injected sub-
cutaneously with 2 × 106 U87 cells stably expressing Vluc 
(through transduction with Lenti-Vluc). Ten days later, mice 
were injected intravenously (iv; through retro-orbital route) or 
intraperitoneally (ip) with vargulin (4 mg/kg body weight) and 
imaged using a cooled charge-coupled device camera at dif-
ferent time points. For iv injected mice, we observed the peak 
luminescent signal immediately upon injection of vargulin, 
which rapidly declined to 25% of initial signal by 6 minutes 
and down to 10% by 26 minutes (Figure 2a). For ip injected 
vargulin, the peak occurred 14 minutes after substrate injec-
tion (Figure 2a). The peak signal for iv route was 2.5-fold 
higher than for ip injection. Thus, vargulin was injected iv 
throughout the study for Vluc imaging.
We then evaluated the possibility of multiplexing Vluc with 
Gluc and Fluc for triple bioluminescence imaging by measuring 
the specificity of each luciferase for its substrate in vivo. U87 
cells stably expressing Vluc, Gluc, or Fluc (under control of the 
cytomegalovirus promoter) were implanted subcutaneously in 
nude mice at three different sites. Ten days later, mice were 
imaged first for Fluc-mediated bioluminescence imaging after 
ip injection of d-luciferin (200 mg/kg body weight) and acquiring 
photon counts 10 minutes after injection. Intense luminescence 
was detected only from tumors expressing Fluc (Figure 2b). 
Twenty-four hours later, mice were imaged immediately after 
iv injection of coelenterazine (5 mg/kg body weight), and again 
signal was obtained only from tumor-expressing Gluc (Figure 
2b). Finally, after another 24 hours, mice were iv injected with 
vargulin (4 mg/kg body weight) and imaged immediately, which 
showed a signal only in tumor-expressing Vluc (Figure 2b). 
Quantification of the luciferase signal from each tumor revealed 
that Fluc and Gluc mediated similar bioluminescence signal, 
whereas Vluc had a significantly lower signal (~100-fold lower; 
n = 3 mice; P = 0.016; Figure 2c).
Sequential monitoring of three biological events in 
response to glioma therapy
We applied the triple luciferase reporter system to monitor 
glioma response to a gene therapeutic approach using the 
secreted soluble variant of the anticancer agent TRAIL.15 We 
Figure 1 In vitro characterization of Vluc-catalyzed luminescence. (a) Vluc assay was performed on conditioned medium as well 
as cell lysates from 293T cells transduced with a lentivirus vector encoding Vluc to determine the fraction (in RLU) of Vluc being secreted 
(n = 3; *P  = 0.003). (b) Vluc light emission kinetics was performed by adding the vargulin substrate to Vluc-containing media (n = 3). 
(c) Stability of Vluc enzyme was determined by assaying an aliquot of Vluc-containing cell-free conditioned medium, incubated at 37 °C, at 
different time points (n = 3). The slight increase observed between day 0 and 4 is not statistically significant (P = 0.176). (d) Vluc-based viability 
assay. 105 U87 cells expressing Vluc were seeded in 12-well plates and an aliquot of conditioned medium was assayed for Vluc activity over 
time. For comparison, a commercially available Fluc-based viability assay was performed on the same cells from which Vluc-media was 
isolated (n = 3 per time point). RLU, relative light unit.
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first cloned sTRAIL under control of the constitutively active 
chicken β-actin (CBA) promoter into an AAV2 inverted termi-
nal repeat-flanked transgene cassette and pseudotyped it with 
an AAVrh.8 capsid (AAV-sTRAIL; Figure 3a). As a control, we 
packaged a similar vector expressing green fluorescent protein 
(GFP) driven by the CBA promoter. We next cloned Vluc cDNA 
under control of CBA promoter in another AAV2 vector pseu-
dotyped with AAVrh.8 capsid (AAV-Vluc; Figure 3a). Vluc was 
used as a marker for gene transfer. We then engineered U87 
glioma cells to stably express Fluc (U87-Fluc) under control 
of cytomegalovirus promoter using a lentivirus vector (Figure 
3a). Fluc was used as a marker for tumor volume. Since TRAIL 
is known to activate a series of events including the nuclear 
factor-κB (NF-κB) pathway, we engineered a lentivirus vec-
tor expressing Gluc under the control of five tandem repeats 
of NF-κB responsive elements (Figure 3a) as described,16 
and used it to transduce the U87-Fluc cells generating U87-
Fluc/NF-Gluc cells. To determine the functionality of the AAV-
sTRAIL construct, we transduced U87 cells with 104 genome 
copy (gc)/cell of AAV-sTRAIL or AAV-GFP control vector. Three 
days later, conditioned media from these cells were harvested 
and analyzed for TRAIL expression using an ELISA kit. We 
observed a TRAIL concentration of 124 ng/ml from conditioned 
medium of AAV-sTRAIL infected cells, while it was undetect-
able in the media from AAV-GFP control cells, displaying the 
proper expression and secretion of sTRAIL into the conditioned 
medium of cells (data not shown). Transfer of conditioned media 
from U87 cells transduced with AAV-sTRAIL onto fresh U87 
cells provided a modest (~25%) yet significant (P = 0.0035) 
killing effect (Supplementary Figure S1).
We then stereotactically implanted 105 U87-Fluc/NF-Gluc 
cells into the striatum of nude mice and allowed tumor for-
mation. Nineteen days later, mice were randomly divided into 
two groups (n = 5/group). The first group was infused into 
the same coordinates used for tumor implantation with 1010 
gc of both AAV-Vluc + AAV-GFP (AAV-Vluc/GFP; serves as 
a negative control for therapy). The second group of mice was 
infused with 1010 gc of both AAV-Vluc (to monitor successful 
gene delivery) and AAV-sTRAIL (antitumor therapy; AAV-Vluc/
sTRAIL). As a control, a set of mice was injected only with AAV-
GFP vector. Ten days after vector injection, we monitored AAV 
gene delivery by injecting mice (iv) with vargulin substrate and 
immediately imaging using a cooled charge-coupled device 
camera. Evident bioluminescent signal (average radiance of 
5 × 105 p/second/cm2/sr ± 2.3 × 104) was seen at the injection 
site of all AAV-Vluc injected mice, and not the AAV-GFP con-
trols, showing successful gene delivery (Figure 3b). Mice in 
both groups were monitored for tumor growth (Fluc imaging) 
at week 2 post-vector injection (corresponding to week 4 post-
tumor injection), which showed a robust antitumor response 
in mice treated with AAV-Vluc/sTRAIL as compared with the 
control group (AAV-Vluc/GFP; Figure 3c).
TRAIL binding to its death receptors recruits TNFR1-asso-
ciated death domain protein (TRADD) leading to NF-κB acti-
vation.17 We therefore sought to detect NF-κB induction and 
therefore TRAIL binding to glioma cells in our model. We first 
confirmed the functionality of the NF-Gluc construct by incu-
bating U87-Fluc/NF-Gluc cells with tumor necrosis factor-α, a 
known activator of NF-κB, and showed a specific induction of 
Gluc expression 48 hours after treatment (Figure 3d). Next, 
mice in both the AAV-Vluc/GFP (control) and AAV-Vluc/sTRAIL 
groups were imaged 22 days and 23 days after AAV injection 
for Fluc and Gluc, respectively. An increase in Fluc signal was 
observed at this time point, showing that tumors regained resis-
tance to sTRAIL therapy (data not shown). As expected, spe-
cific Fluc bioluminescence at the tumor location was observed 
in both groups of mice, but visible Gluc signal was detected only 
in mice injected with AAV-Vluc/sTRAIL and not AAV-Vluc/GFP 
control animals, indicating binding of sTRAIL to glioma cells 
and induction of the downstream NF-κB pathway (Figure 3e,f). 
All together, these results show that the triple luciferase system 
developed here could be used to image three independent cel-
lular processes sequentially in the same animal model.
We next performed an extensive analysis of AAV-mediated 
sTRAIL therapy in mice bearing intracranial U87 tumors. Ten 
mice were injected with 5 × 104 U87-Fluc/NF-Gluc cells into 
the striatum as above, and 14 days later, mice were random-
ized into two groups (n = 5/group) where the first group was 
infused into the same tumor implanted site with 1010 gc of a 
combination of AAV-Vluc/GFP and the second group with the 
same amount of AAV-Vluc/sTRAIL. Mice were imaged at day 
2, 7, 14, and 21 after vector injection for tumor-associated 
Figure 2 Triple in vivo bioluminescence imaging. (a) 2 × 106 U87 glioma cells stably expressing Vluc were implanted subcutaneously in 
nude mice. Tumor-associated Vluc signal after iv or ip injection of 4 mg/kg vargulin is shown by a representative mouse from each injection 
route (n = 3). (b) U87 glioma cells stably expressing Gluc, Vluc or Fluc were injected subcutaneously in nude mice at different sites. Ten days 
later, sequential imaging of Fluc, Gluc, and Vluc was performed (1 day apart) after injection of d-luciferin, coelenterazine, and vargulin. A 
representative mouse from each imaging session is shown (n = 3). (c) A region of interest (ROI) was drawn around each tumor location and 
photons/second were calculated.
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Fluc signal. Similar to the first experiment, AAV-mediated 
sTRAIL expression slowed the tumor growth as compared 
with control mice. At day 2 after vector injection, the AAV-
Vluc/GFP control group had a twofold higher signal (P = 
0.46) as compared with the AAV-Vluc/sTRAIL-treated mice 
(Figure 4a,b). This difference increased to 6.13- (P = 0.048) 
and 33.7-fold (P = 0.0008) on day 7 and 14, respectively. All 
mice in the AAV-Vluc/GFP group were sacrificed between 
day 14 and 21 after vector injection due to tumor burden, 
while the entire group in AAV-Vluc/sTRAIL remained alive. 
Interestingly, the AAV-Vluc/sTRAIL group showed a 193-
fold increase in the Fluc signal (and therefore tumor growth) 
between days 14 and 21, presumably due to U87-gained 
resistance to sTRAIL therapy (Figure 4a,b). We also per-
formed an experiment with a higher input of U87 cells and 
obtained similar results  (Supplementary  Figure S2). We 
confirmed the luminescence data with a survival analysis, 
which revealed a significant survival increase (P  = 0.0088) 
for mice injected with AAV-Vluc/sTRAIL compared with AAV-
Vluc/GFP controls (Figure 4c). The median survival time for 
the AAV-Vluc/GFP group was 35 days while it was 80 days 
for the AAV-Vluc/sTRAIL group.
Discussion
Luciferases have played a major role in advancing our under-
standing of biological processes. A broader array of biocom-
patible, nontoxic, and efficiently expressed reporters that can 
be used together with existing luciferases can serve to expand 
this potential. The present study demonstrates for the first time 
a triple luciferase reporter system for in vivo bioluminescence 
imaging. We showed that Vargula luciferase could be multi-
plexed with Gaussia and firefly luciferases for sequential moni-
toring of three distinct biological phenomena. We also showed 
Figure 3 Monitoring of sTRAiL-mediated gene therapy with triple bioluminescence imaging. (a) Schematic diagram for the different 
AAV (left) and lentivirus (right) vector constructs used in this study. AAV vectors: CMV E, cytomegalovirus enhancer; CBA, chicken β-actin 
promoter; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element; pA, bGH poly A signal. Lentivirus vectors: Diagrams shown 
represent integrated provirus. CMV IE, cytomegalovirus immediate early promoter; cHS4 INS, chicken β globin hypersensitive site 4 insulator 
sequence; NF, nuclear factor-κB inducible promoter. (b–f) 105 U87-Fluc/NF-Gluc glioma cells were implanted intracranially in nude mice. 
Nineteen days later, the mice brains were infused at the same tumor injection site with 1010 gc of either AAV-Vluc/GFP, AAV-Vluc/sTRAIL, or 
AAV-GFP alone. (b) Vluc bioluminescence imaging performed 10 days after vector injection confirming AAV-mediated gene delivery. (c) Two 
weeks post-vector injection, tumor volume was imaged by Fluc bioluminescence imaging. (d) Confirmation of NF-Gluc construct. U87-Fluc/
NF-Gluc cells in culture were treated with or without tumor necrosis factor-α (TNF-α) (10 ng/ml). Forty-eight hours later, conditioned medium 
were collected and assayed for Gluc activity to detect levels of NF-κB induction (*P = 0.0001). (e,f) NF-Gluc imaging, a marker for TRAIL 
binding on glioma cells performed after iv injection of coelenterazine. Calculation of NF-κB activation in glioma-bearing mice treated with AAV-
Vluc/sTRAIL or AAV-Vluc/GFP shown in f. Note that no Gluc signal was detected in the AAV-Vluc/GFP mice at any time point. Representative 
mice from each group are showing in (b,c, and e; n = 5/group). ITR, inverted terminal repeat; nd, not detected.
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that this triple bioluminescence imaging system yield specific, 
and detectable bioluminescence signal in deep tissues such as 
the brain (with intact skull, ~3.5 mm) of mice. Finally, we applied 
these reporters to monitor three cellular processes in an ortho-
topic brain tumor model in response to AAV-sTRAIL therapy, 
thus validating the system for different applications.
Since the cloning and sequencing of Vargula (formerly 
Cypridina) hilgendorfii cDNA in 1989,13 several reports have 
demonstrated the usefulness of this enzyme for lumines-
cence assays.18–21 However, to our knowledge, no reports 
have applied it for in vivo imaging in mammals, probably 
owing to the unavailability of its substrate vargulin, which 
is now commercially available. Vluc cDNA possess a signal 
sequence and therefore it is naturally secreted from cells 
allowing real time, multi–time point analysis from the same 
well.18,22 In this study, we characterized a codon-optimized 
Vluc cDNA for mammalian gene expression and showed 
Vluc to be very stable with no significant decline in activ-
ity over 12 days in cell-free conditioned media at 37 °C. 
Despite that the majority of Vluc was found in the condi-
tioned media of cells due to its native signal sequence, the 
intracellular Vluc level was efficient for in vivo imaging. In 
applications where higher sensitivity is required, a mem-
brane-bound variant of Vluc22 could be used, which should 
yield higher cellular activity similar to recent reports for 
Gaussia luciferase.23,24
Several systems for multimodal imaging exist, which incor-
porate different technologies such as fluorescence, biolu-
minescence, positron emission tomography, and magnetic 
resonance imaging.25 While substantial multiparameter infor-
mation can be gained by these systems, they have several 
drawbacks, including higher cost (e.g., magnetic resonance 
imaging), logistical concerns such as short half-life of some 
positron emission tomography probes, and broad techni-
cal expertise. While fluorescent reporter-based imaging as 
well as luciferases emitting at different wavelengths can be 
used for multimodal applications, they require expensive 
and complicated instrumentation with spectral deconvolu-
tion to visualize each biological parameter.26,27 Furthermore, 
fluorescence-based imaging is limited by a high background 
noise due to tissue autofluorescence as well as single animal 
analysis. On the other hand, BLI has low-to-no background 
and is thus more sensitive for deep tissue applications.28 The 
triple in vivo bioluminescence imaging system described here 
yields multiparameter information distinguished by sequen-
tial imaging using different specific substrates, while remain-
ing both cost-effective and highly sensitive, as well as being 
user friendly; only a simple charge-coupled device camera is 
required with no need for sophisticated instrument hardware/
software. Moreover, this same system can be extended and 
applied to any field to monitor three distinct biological phe-
nomena in small animals. It is important to note, however, 
that we have tested Vluc expression in the brain of mice bear-
ing intracranial tumors. Since tumors may have comprised 
the integrity of the blood–brain barrier, it would be important 
to evaluate vargulin in a model with intact blood–brain barrier 
to validate the ability of this substrate in crossing this biologi-
cal barrier. Another drawback of the triple-reporter system is 
Figure 4 Effect of AAV-sTRAiL vector on U87 glioma tumors. (a,b) 5 × 104 U87 glioma cells expressing Fluc, a marker for tumor volume, 
were implanted in the brain of nude mice. Fourteen days later, mice were randomized into two groups and infused into the same tumor injection 
site with either AAV-Vluc/GFP or AAV-Vluc/sTRAIL (n = 5/group). Mice were imaged for Fluc at days 2, 7, 14, and 21 after vector injection. 
(a) Representative set of mice from each group are shown. Note that the scale is different for each time point in order to show the tumor site. 
(b) Quantitation of brain tumor-associated Fluc signal in mice over time. The arrow indicates that all mice in the AAV-Vluc/GFP group were 
sacrificed between week 2 and week 3 due to tumor burden (*P = 0.048 at day14 and *P = 0.0008 at day 21). (c) Survival analysis of mice 
bearing U87 glioma tumors treated with either AAV-Vluc/GFP or AAV-Vluc/sTRAIL (n = 5; P = 0.0088). All Graphs are generated from a 
representative data set of three independent experiments.
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the need of methanol to dissolve the vargulin and coelentera-
zine substrates, limiting imaging frequency due to potential 
toxicity of the alcohol. The use of water-soluble coelentera-
zine29 or the development of similar vargulin substrate would 
alleviate this issue.
TRAIL has been regarded as an anticancer agent; how-
ever, significant cancer types, including gliomas, are resis-
tant to TRAIL-induced cell death.30 Mechanisms of resistance 
include downregulation of death receptors,29 decoy receptor 
expression,30 as well as overexpression of the caspase-8 
inhibitor, c-FLIP, due to deregulation of the mTOR signaling 
pathway.31 In addition, NF-κB induction by TRAIL has been 
reported as a tumor cell resistance mechanism.32,33 Another 
disadvantage of using TRAIL for brain tumor therapy is its 
inability in crossing the blood–brain barrier. In this study, we 
circumvented this problem by delivering sTRAIL directly to 
brain tumor environment using AAV-mediated gene deliv-
ery. We chose to use AAVrh.8 as we have previously shown 
that this serotype yields excellent transduction efficiency of 
murine normal brain.34 Injection of AAVrh.8 into the tumor 
results in transduction of primarily neuronal cells surrounding 
the tumor.34 The transduced neurons serve as a therapeutic 
reservoir surrounding the tumor by synthesizing and secret-
ing sTRAIL, which in turn will find and bind its death receptor 
present specifically on glioma cells. Despite this continu-
ous release of the anticancer agent by the normal brain, we 
observed that tumors acquired resistance to sTRAIL therapy; 
however, a significant increase in survival was observed 
using AAV-mediated expression of sTRAIL compared with 
the control group. The exact mechanism of TRAIL resistance 
in this model is currently not known, but may involve NF-κB 
signaling, as mice injected with AAV-Vluc/sTRAIL showed 
activation of the NF-κB transcription factor, as monitored 
by Gluc imaging. It is noteworthy to mention that U87 cells 
showed low sensitivity to sTRAIL-mediated death in cul-
ture, as compared with the initial high sensitivity in vivo. This 
apparent discrepancy may be explained by several factors. 
The culture experiment used conditioned medium from cells 
secreting sTRAIL (124 ng/ml as determined by ELISA) and 
therefore the cells will only get a “one-shot” delivery, given 
that toxicity of TRAIL to glioma cells is dose-dependent.35 
Similar results were reported by Yang et al. (25% killing) 
using a dose of 100 ng/ml of sTRAIL in culture.36 Although 
the level of AAV-mediated sTRAIL expression in the brain is 
unknown, the transduction efficiency of the vector serotype 
used (AAVrh.8) is very high in the murine brain.37 Similar to 
our findings, Yang et al. reported that despite this apparent 
low TRAIL-sensitivity in vitro, an increase in survival rate in 
vivo was observed when using mesenchymal stem cell to 
deliver sTRAIL to U87 gliomas.36 Finally, resistance factors 
that allow glioma cell survival in culture may not suffice for 
in vivo tumor growth in a complex multicellular environment.
In conclusion, we have developed a triple luciferase sys-
tem for in vivo bioluminescence applications. We showed 
that each of these luciferases (Vluc, Gluc, and Fluc) is spe-
cific to its own substrate and can be multiplexed together to 
monitor three distinct biological events in the same biological 
system. This reporter system could be extended to different 
fields where simultaneous monitoring of multiple parameters 
is required.
Materials and methods
Cells. U87 human glioblastoma cell line and 293T human 
kidney fibroblast cells were obtained from the American Type 
Culture Collection (Manassas, VA). Both cell lines were cul-
tured in high glucose Dulbecco’s modified Eagle’s medium 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal 
bovine serum (Sigma, St Louis, MO) and 100 U/ml penicil-
lin, 100 μg/ml streptomycin (Invitrogen) in a humidified atmo-
sphere supplemented with 5% CO2 at 37 °C.
AAV vectors and lentivirus vectors. The AAV-CBA-Vluc vec-
tor was constructed by replacing EGFP in AAV-CBA-EGFP38 
with the human codon-optimized Vluc cDNA (a kind gift from 
Dr Rampyari Walia; Targeting Systems, El Cajon, CA). AAV-
CBA-sTRAIL vector consists of a transgene cassette for sol-
uble, secreted TRAIL carrying amino acid (aa) 1–150 from 
human Flt3L, an isoleucine zipper domain, and the extracel-
lular domain (aa 114–281) of the human TRAIL designed 
based on previously reported h-Flex-zipper-TRAIL.15 In all 
AAV vectors, gene expression is controlled by a hybrid cyto-
megalovirus enhancer/CBA. All vectors carry a woodchuck 
hepatitis virus post-trancriptional regulatory element (WPRE) 
downstream of the transgene. AAV vector stocks were pro-
duced by cotransfection of 293T cells by calcium phosphate 
precipitation of vector plasmid, a mini-adenovirus helper 
plasmid pFΔ6 (from Dr Weidong Xiao, University of Pennsyl-
vania Medical Center, Philadelphia, PA), and AAVrh.8 helper 
plasmid pAR8 as described.38 AAV2/rh.8 vectors were puri-
fied and titered as described,38 yielding typical titers of 1013 
genome copies (gc) per milliliter.34 For sTRAIL expression 
in culture, AAV vectors were packaged as AAV2 since this 
serotype is known to transduce cells in culture much more 
efficiently as compared with AAV2/rh.8.
U87Fluc-mCherry cells stably and constitutively express-
ing both firefly luciferase (Fluc) and mCherry were generated 
by transduction with lentiviral vector CSCW2-Fluc-ImCherry, 
which has been previously described.34 U87Fluc-mCherry 
cells were subsequently transduced with a lentivirus previ-
ously described as Lenti-NF-Gluc, which encodes a Gluc 
transgene cassette driven by five tandem repeats of NF-κB–
responsive elements.16 This double-transduced U87 cells is 
referred to as U87Fluc/NF-Gluc cells. The lentivirus vector 
encoding Vluc was constructed by replacing the Fluc insert 
in CSCW2-Fluc-ImCherry with the human codon-optimized 
Vluc cDNA. We achieve >95% transduction efficiency of U87 
cells at a multiplicity of infection of 10 with the different lenti-
virus constructs. We do not find it necessary to sort the cells 
owing to this high transduction rate.
In vivo tumor models. All animal experiments were approved 
by the Massachusetts General Hospital Subcommittee on 
Research Animal Care following guidelines set forth by the 
National Institutes of Health Guide for the Care and Use of 
Laboratory Animals. Six to 8 weeks old athymic nude mice 
were anesthetized with a mixture of ketamine (100 mg/kg) 
and xylazine (5 mg/kg) in 0.9% sterile saline. For subcutane-
ous tumors, mice were injected with 100 μl of a 50:50 mixture 
of Matrigel Basement Membrane Matrix (BD Biosciences, 
Franklin Lakes, NJ) and 1–2 million U87 cells expressing 
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Gluc, Vluc, or Fluc resuspended in Opti-MEM. For the brain 
tumor model, 105 U87Fluc/5NF-Gluc cells (in 2 μl Opti-MEM) 
were intracranially injected in the left midstriatum of nude 
mice using the following coordinates from bregma in milli-
meters: anteroposterior +0.5, mediolateral +2.0, and dorso-
ventral −2.5. These injections were performed using a Micro 
4 Microsyringe Pump Controller (World Precision Instru-
ments, Sarasota, FL) attached to a Hamilton syringe with a 
33-gauge needle (Hamilton, Reno, NV) at a rate of 0.2 μl/
min. Before AAV vector injection, mice were randomized into 
separate groups by placing all mice into a single cage by one 
operator and selected for each group by a different operator. 
For AAV vector injections, mice were anesthetized as above 
and injected intracranially with 1010 gc of each vector using 
the same coordinates as for tumor injections. AAV vectors 
were infused at a rate of 0.2 μl/min using a Micro 4 Microsy-
ringe Pump Controller attached to a Hamilton syringe with a 
33-G needle.
In vitro and in vivo luciferase imaging. d-luciferin was pur-
chased from Gold Biotechnology (St Louis, MO) and resus-
pended at 25 mg/ml in phosphate-buffered saline. For Fluc 
imaging, mice were injected ip with 200 mg/kg body weight 
of d-luciferin solution, and imaging was performed 10 min-
utes later. Coelenterazine was obtained from NanoLight™ 
Technology (Pinetop, AZ) and resuspended at 5 mg/ml in 
acidified methanol. For Gluc imaging, mice were injected 
iv (through retro-orbital route) with 5 mg/kg body weight of 
coelenterazine solution diluted in phosphate-buffered saline 
and imaging was performed immediately. Vargulin substrate 
was obtained from NanoLight Technology or from Targeting 
Systems and was resuspended at 5 mg/ml in acidified metha-
nol. For monitoring cell proliferation with Vluc, we refreshed 
the media of cells 4 hours before measurements to avoid 
accumulation of the reporter. For Vluc in vivo imaging, mice 
were injected iv (unless otherwise noted) with 4 mg/kg body 
weight (diluted in phosphate-buffered saline), and imaging 
was performed immediately. For sequential imaging of all 
three reporters, we imaged Fluc on day 1, Gluc on day 2, and 
Vluc on day 3, allowing 24 hours waiting period between the 
different imaging sessions. Imaging was performed using an 
IVIS Spectrum optical imaging system fitted with an XGI-8 
Gas Anesthesia System (Caliper Life Sciences, Hopkinton, 
MA). Bioluminescent images were acquired using the auto-
exposure function. Data analysis for signal intensities, and 
image comparisons were performed using Living Image soft-
ware (Caliper Life Sciences). To calculate radiance for each 
animal, regions of interest were carefully drawn around each 
signal, which is expressed as radiance (photons/second/cm2/
steradian).
TRAIL ELISA. The functionality of the AAV-sTRAIL vector 
was tested by transducing U87 cells with 104 gc/cell with 
AAV2-sTRAIL or a negative control vector AAV2-GFP. Three 
days later, media was harvested from all wells and a Quanti-
kine Human TRAIL ELISA (R&D Systems, Minneapolis, MN) 
was performed as per the manufacturer’s instructions.
Data presentation and calculations. For experiment in 
 Figure 1a, we calculated total relative light unit (RLU) in media 
and cell lysate as follows: (RLU/volume assayed) × total vol-
ume in cell lysate or media. To calculate the percentage of 
secreted Vluc, we used the following equation: (Total RLU in 
media)/(Total RLU in media + Total RLU in cell lysate) × 100.
To calculate Gluc Flux in Figure 3f, we first divided Fluc 
values (tumor size) for each mouse to the lowest Fluc value 
of the three mice (arbitrarily set to one). Next the Gluc values 
were divided by each of the adjusted values to get the Gluc 
flux, which was adjusted for tumor size.
Statistical analysis. Statistical analysis was performed using 
GraphPad Prism version 5.01 software (La Jolla, CA). For 
comparisons between two samples, an unpaired two-tailed 
t-test was performed. A P value of <0.05 was considered 
to be statistically significant. For analysis between multiple 
groups, a one-way analysis of variance was performed fol-
lowed by a Bonferroni’s multiple comparison test to compare 
two groups.
Supplementary material
Figure S1. U87 glioma cells are moderately sensitive to kill-
ing by conditioned media from donor cells transduced with 
AAV-sTRAIL.
Figure S2. Effect of AAV-sTRAIL vector in mice bearing 
U87 glioma tumors.
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